Cargando…
How the immune system responds to therapeutic biological agents
Biological agents target disease mechanisms and have modified the natural history of several immune-mediated disorders. Biological agents are structurally immunogenic, and therefore usually elicit a minor, subclinical and transient phenomenon. Occasionally, however, these drugs induce complete cellu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536528/ https://www.ncbi.nlm.nih.gov/pubmed/27683137 http://dx.doi.org/10.1177/0300060515593248 |
_version_ | 1783254025443999744 |
---|---|
author | Vultaggio, Alessandra Petroni, Giulia Pratesi, Sara Nencini, Francesca Cammelli, Daniele Ferraro, Andrea Maggi, Enrico Matucci, Andrea |
author_facet | Vultaggio, Alessandra Petroni, Giulia Pratesi, Sara Nencini, Francesca Cammelli, Daniele Ferraro, Andrea Maggi, Enrico Matucci, Andrea |
author_sort | Vultaggio, Alessandra |
collection | PubMed |
description | Biological agents target disease mechanisms and have modified the natural history of several immune-mediated disorders. Biological agents are structurally immunogenic, and therefore usually elicit a minor, subclinical and transient phenomenon. Occasionally, however, these drugs induce complete cellular and humoral immune responses, with the main clinical consequences being hypersensitivity reactions or loss of treatment response. This article considers the relative pathogenic mechanisms influencing immunogenicity in biological agents and discusses mechanisms of tolerance and adaptive immune response, including adaptive T-regulatory cell induction and immune response induction. Methods of determining cellular and humoral immune response to biological agents are identified and examined. Assays to detect antidrug antibodies and their isotypes can assist in monitoring immunogenicity and in preventing adverse events. Such strategies also enable resource conservation and may provide regulatory authorities with new insights that can be useful during the process of approving new biological or biosimilar agents. |
format | Online Article Text |
id | pubmed-5536528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-55365282017-10-03 How the immune system responds to therapeutic biological agents Vultaggio, Alessandra Petroni, Giulia Pratesi, Sara Nencini, Francesca Cammelli, Daniele Ferraro, Andrea Maggi, Enrico Matucci, Andrea J Int Med Res Immuno-Mediated Diseases and Treatment Immunogenicity Biological agents target disease mechanisms and have modified the natural history of several immune-mediated disorders. Biological agents are structurally immunogenic, and therefore usually elicit a minor, subclinical and transient phenomenon. Occasionally, however, these drugs induce complete cellular and humoral immune responses, with the main clinical consequences being hypersensitivity reactions or loss of treatment response. This article considers the relative pathogenic mechanisms influencing immunogenicity in biological agents and discusses mechanisms of tolerance and adaptive immune response, including adaptive T-regulatory cell induction and immune response induction. Methods of determining cellular and humoral immune response to biological agents are identified and examined. Assays to detect antidrug antibodies and their isotypes can assist in monitoring immunogenicity and in preventing adverse events. Such strategies also enable resource conservation and may provide regulatory authorities with new insights that can be useful during the process of approving new biological or biosimilar agents. SAGE Publications 2016-09-28 2016-09 /pmc/articles/PMC5536528/ /pubmed/27683137 http://dx.doi.org/10.1177/0300060515593248 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Immuno-Mediated Diseases and Treatment Immunogenicity Vultaggio, Alessandra Petroni, Giulia Pratesi, Sara Nencini, Francesca Cammelli, Daniele Ferraro, Andrea Maggi, Enrico Matucci, Andrea How the immune system responds to therapeutic biological agents |
title | How the immune system responds to therapeutic biological agents |
title_full | How the immune system responds to therapeutic biological agents |
title_fullStr | How the immune system responds to therapeutic biological agents |
title_full_unstemmed | How the immune system responds to therapeutic biological agents |
title_short | How the immune system responds to therapeutic biological agents |
title_sort | how the immune system responds to therapeutic biological agents |
topic | Immuno-Mediated Diseases and Treatment Immunogenicity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536528/ https://www.ncbi.nlm.nih.gov/pubmed/27683137 http://dx.doi.org/10.1177/0300060515593248 |
work_keys_str_mv | AT vultaggioalessandra howtheimmunesystemrespondstotherapeuticbiologicalagents AT petronigiulia howtheimmunesystemrespondstotherapeuticbiologicalagents AT pratesisara howtheimmunesystemrespondstotherapeuticbiologicalagents AT nencinifrancesca howtheimmunesystemrespondstotherapeuticbiologicalagents AT cammellidaniele howtheimmunesystemrespondstotherapeuticbiologicalagents AT ferraroandrea howtheimmunesystemrespondstotherapeuticbiologicalagents AT maggienrico howtheimmunesystemrespondstotherapeuticbiologicalagents AT matucciandrea howtheimmunesystemrespondstotherapeuticbiologicalagents |